AGITG 2013* Presentation 1: Do patients achieving pathological complete response (pCR) following neoadjuvant treatment for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? Speaker: Dr Anis Hamid Institution: Austin HealthPresentation 2: Natural killer cells in rectal cancers treated with neoadjuvant chemoradiotherapy Speaker: Dr Stephanie LimInstitution: Ingham Research InstitutePresentation 3: Do regulatory T cells inhibit the response of rectal carcinomas to neoadjuvant chemoradiotherapy? Speaker: Dr Melanie McCoy Institution: St John of God Health CarePresentation 4: Circulating tumour DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapySpeaker: Dr Jeanne Tie Institution: Royal Melbourne Hospital
Presentation 1: Do patients achieving pathological complete response (pCR) following neoadjuvant treatment for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? Speaker: Dr Anis Hamid Institution: Austin HealthPresentation 2: Natural killer cells in rectal cancers treated with neoadjuvant chemoradiotherapy Speaker: Dr Stephanie LimInstitution: Ingham Research InstitutePresentation 3: Do regulatory T cells inhibit the response of rectal carcinomas to neoadjuvant chemoradiotherapy? Speaker: Dr Melanie McCoy Institution: St John of God Health CarePresentation 4: Circulating tumour DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapySpeaker: Dr Jeanne Tie Institution: Royal Melbourne Hospital